<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482495</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000546757</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0584</secondary_id>
    <secondary_id>05-004261</secondary_id>
    <nct_id>NCT00482495</nct_id>
  </id_info>
  <brief_title>Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase II Trial of Bevacizumab in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of multiple myeloma by blocking blood flow to the cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with&#xD;
      relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the hematologic response rate in patients with relapsed or refractory multiple&#xD;
           myeloma treated with bevacizumab.&#xD;
&#xD;
        -  Determine the proportion of patients who are progression free and have not failed&#xD;
           treatment after 1 year.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patient.&#xD;
&#xD;
        -  Determine the time to disease progression in patients receiving this drug.&#xD;
&#xD;
        -  Determine the overall survival and survival at 1 year in patients receiving this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive bevacizumab IV on day 1. Treatment repeats every 21 days for 4 courses in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are obtained for correlative studies at baseline, after course 2, and at 12&#xD;
      weeks. Samples are analyzed for interleukin-6, Flt-1, and VEGF levels.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3-6 months for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed hematologic response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival at 1 year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of relapsed or refractory multiple myeloma&#xD;
&#xD;
          -  Measurable or evaluable disease as defined by ≥ 1 of the following:&#xD;
&#xD;
               -  Serum monoclonal protein ≥ 1.0 g by protein electrophoresis&#xD;
&#xD;
               -  Monoclonal protein ≥ 200 mg by 24-hour urine electrophoresis&#xD;
&#xD;
               -  Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum&#xD;
                  immunoglobulin kappa to lambda free light chain ratio&#xD;
&#xD;
               -  Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)&#xD;
&#xD;
          -  No concurrent amyloidosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0 or 1&#xD;
&#xD;
               -  ECOG PS 2 based on immobility from myeloma bone disease alone allowed at the&#xD;
                  discretion of treating physician&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  ANC ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Proteinuria ≤ 1 g/dL by 24-hour urine collection (excluding monoclonal protein)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
          -  No hypertension (defined as BP &gt; 150/100 mm Hg)&#xD;
&#xD;
          -  No active bleeding, healing or nonhealing wound, ulcer, or bone fracture (excluding&#xD;
             fractures secondary to myeloma)&#xD;
&#xD;
          -  No active ulcerative disease including, but not limited to, any of the following:&#xD;
&#xD;
               -  Peptic ulcer disease&#xD;
&#xD;
               -  Ulcerative esophagitis&#xD;
&#xD;
               -  Ulcerative colitis&#xD;
&#xD;
               -  Crohn's disease&#xD;
&#xD;
          -  LVEF ≥ 50% by 2-dimensional ECHO or MUGA scan&#xD;
&#xD;
          -  No NYHA class III or IV heart disease&#xD;
&#xD;
          -  No other active malignancy except for nonmelanoma skin cancer or in situ cervical or&#xD;
             breast cancer&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other comorbidity that would interfere with study compliance&#xD;
&#xD;
          -  No transient ischemic attack, cerebrovascular accident, or myocardial infarction&#xD;
             within the past year&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within&#xD;
             the past 6 months&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior antimyeloma treatment courses, except for bisphosphonates&#xD;
&#xD;
          -  No standard or experimental drug therapy, other than ongoing bisphosphonate treatment&#xD;
             and/or epoetin alfa, within the past 28 days&#xD;
&#xD;
          -  No experimental non-drug therapy within the past 28 days&#xD;
&#xD;
          -  Palliative radiation therapy within the past 28 days allowed provided ≤ 3 sites of&#xD;
             bone disease was irradiated&#xD;
&#xD;
          -  No prior bevacizumab or other experimental antiangiogenic agents other than&#xD;
             thalidomide or lenalidomide&#xD;
&#xD;
          -  No minor surgical procedures, fine-needle aspiration, or core biopsies within the past&#xD;
             7 days&#xD;
&#xD;
          -  No major surgical procedure or open biopsy within the past 28 days&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
               -  Chronic steroids ≤ 20 mg/day (prednisone equivalent) for disorders other than&#xD;
                  myeloma (i.e., adrenal insufficiency, rheumatoid arthritis) allowed&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent systemic antineoplastic therapy including, but not limited to, the&#xD;
             following:&#xD;
&#xD;
               -  Cytotoxic chemotherapy&#xD;
&#xD;
               -  Immunotherapy&#xD;
&#xD;
               -  Hormonal therapy&#xD;
&#xD;
               -  Monoclonal antibody therapy&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Hayman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>May 10, 2011</last_update_submitted>
  <last_update_submitted_qc>May 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Suzanne R. Hayman, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

